Aim: Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is an immune inhibitory receptor which is expressed within most types of hematopoietic cells and negatively regulates immune responses. Recently, we found LAIR-1 expression to be present within tumors of nonhematopoietic lineages. However, the roles of LAIR-1 in hepatocellular carcinoma (HCC) have yet to be examined. The purpose of this study was to investigate the expression of LAIR-1 in HCC tissue and assess its clinical significance at this site.
Materials And Methods: Expression levels of LAIR-1 within HCC samples collected from 90 patients and compared with that of slides of normal liver tissue collected from 9 non-HCC patients were measured by immunohistochemistry using tissue microarrays. A semiquantitative score was assigned, as was based on staining intensity and percent of positive cells and a Spearman Rank correlation test was used to assess any potential significant correlations between LAIR-1 expression and clinicopathological factors. Overall survival analysis was performed using the Kaplan-Meier and Log Rank statistical test.
Results: LAIR-1 expression was detected in cancer tissue and adjacent tumor tissue, but not in normal liver tissue. The percent of LAIR-1-positive expression in cancer tissue of HCC samples was 97.78% (88/90) while that in adjacent tumor tissue was 96.67% (87/90). Significantly greater expression levels of LAIR-1 were obtained from cancer tissue (Mean ± SD = 5.722 ± 2.145) than that in adjacent tumor tissue (4.141 ± 1.486). In addition, LAIR-1 expression was found to be significantly correlated with pathological grade of HCC, T stage, and age. Expression levels of LAIR-1 were related with worse overall survival rates of HCC patients, especially in HCC patients with hepatic cirrhosis.
Conclusion: Results of this study show that LAIR-1 is expressed in HCC tissues and that high levels of LAIR-1 expression are associated with the poor cancer differentiation. In addition, overexpression of LAIR-1 was significantly associated with worse overall survival in the patients with HCC. These data suggest that LAIR-1 may be an independent predictor for clinical outcomes in patients with HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.currproblcancer.2018.04.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subtype-specific analysis of gene co-expression networks and immune cell profiling reveals high grade serous ovarian cancer subtype linkage to variable immune microenvironment.
J Ovarian Res
December 2024
Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, 720 Westview Dr SW, HG 341B, Atlanta, GA, 30310, USA.
Article Synopsis
- High-grade serous ovarian cancer (HGSOC) is a complex and aggressive cancer type marked by significant molecular diversity, challenging current treatment efforts.
- This study analyzed four mRNA subtypes—immunoreactive, differentiated, proliferative, and mesenchymal—focusing on their gene expression profiles, immune microenvironment, and connections to clinical traits like survival and age.
- Key findings showed that the immunoreactive subtype had high immune cell infiltration linked to better immune responses, while the proliferative subtype was associated with growth and cancer progression, highlighting the need for subtype-specific treatment strategies.
Leukemic B cells expression of CD200 and Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1, CD305) in Chronic Lymphocytic Leukemia patients in relation to Treg frequency.
Pathol Res Pract
November 2024
Biochemistry Department, Faculty of Pharmacy, Ain Shams University, Abbasia, Cairo 11566, Egypt. Electronic address:
Background: Chronic lymphocytic leukemia (CLL) is characterized by a wide range of tumor-induced immune alterations. Regulatory T cells (Treg) play a central role in these immune responses. CD200 and Leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1, CD305) are inhibitory markers said to be involved in Treg immune response.
View Article and Find Full Text PDFLAIR-1 and PECAM-1 function via the same signaling pathway to inhibit GPVI-mediated platelet activation.
Res Pract Thromb Haemost
August 2024
Institut National de la Santé et de la Recherche Médicale (INSERM), Etablissement Français du Sang (EFS) Grand-Est, Unité Mixte de Recherche (UMR)-S 1255, Université de Strasbourg, Strasbourg, France.
Background: Inhibition of platelet responsiveness is important for controlling thrombosis. It is well established that platelet endothelial cell adhesion molecule-1 (PECAM-1) serves as a physiological negative regulator of platelet-collagen interactions. We recently demonstrated that leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) is a negative regulator of platelet production and reactivity.
View Article and Find Full Text PDFImpaired LAIR-1-mediated immune control due to collagen degradation in fibrosis.
J Autoimmun
June 2024
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands. Electronic address:
Tissue repair is disturbed in fibrotic diseases like systemic sclerosis (SSc), where the deposition of large amounts of extracellular matrix components such as collagen interferes with organ function. LAIR-1 is an inhibitory collagen receptor highly expressed on tissue immune cells. We questioned whether in SSc, impaired LAIR-1-collagen interaction is contributing to the ongoing inflammation and fibrosis.
View Article and Find Full Text PDF[leukocyte-associated immunoglobulin-like receptor 1 (LAIR-1) inhibits proliferation and promotes apoptosis of human HEL cells with JAK2 V617F mutation by blocking the JAK/STAT and PI3K/AKT signaling pathways].
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
March 2024
Department of Immunology of Basic Medical College, Binzhou Medical University, Yantai 264000, China. *Corresponding author, E-mail:
Objective To investigate the role of human leukocyte-associated immunoglobulin-like receptor-1 (LAIR-1) in the regulation of Janus kinase/signal transducers and activators of transcription (JAK/STAT) and phosphatidylinositol 3 kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT /mTOR) signaling pathways in human acute myeloid leukemia HEL cells carrying the JAK2 V617F mutation, along with its effects on cell proliferation and apoptosis. MethodsThe JAK2 V617F mutation was identified using reverse transcription PCR and gene sequencing. The protein phosphatase (PTP) recruited by LAIR-1 was determined through co-immunoprecipitation and Western blot analysis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!